PubMed:32522282 / 206-686
Annnotations
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T6 | 99-109 | CHEBI:33282 | denotes | antibiotic |
| T7 | 99-109 | CHEBI:33282 | denotes | antibiotic |
| T8 | 110-122 | CHEBI:2955 | denotes | azithromycin |
| T9 | 110-122 | CHEBI:2955 | denotes | azithromycin |
| T10 | 110-122 | DG_6 | denotes | azithromycin |
| T11 | 127-145 | CHEBI:5801 | denotes | hydroxychloroquine |
| T12 | 127-145 | CHEBI:5801 | denotes | hydroxychloroquine |
| T13 | 127-145 | DG_20 | denotes | hydroxychloroquine |
| T14 | 168-174 | UBERON:0002405 | denotes | immune |
| T15 | 175-185 | GO:0065007 | denotes | modulation |
| T16 | 307-315 | SP_7 | denotes | COVID-19 |
| T17 | 450-469 | UBERON:0007221 | denotes | intensive care unit |
| T18 | 474-479 | GO:0016265 | denotes | death |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T2 | 155-167 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
| T3 | 241-251 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T4 | 307-315 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 4-7 | http://purl.obolibrary.org/obo/PR_000001343 | denotes | aim |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 99-109 | Chemical | denotes | antibiotic | http://purl.obolibrary.org/obo/CHEBI_33281 |
| T2 | 110-122 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T3 | 127-145 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T4 | 187-196 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 155-167 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 0-480 | Sentence | denotes | The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death. |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 0-480 | Sentence | denotes | The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death. |
| T4 | 0-480 | Sentence | denotes | The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death. |